RenovoRx Raises $10 Million in Oversubscribed Private Placement

RenovoRx ( (RNXT) ) has issued an update.

On March 17, 2026, RenovoRx entered into securities purchase agreements for an oversubscribed private placement of common stock, pre-funded warrants and milestone-based warrants with institutional investors and company insiders, closing on March 20, 2026 and raising approximately $10 million in gross proceeds. The at-market financing, structured with revenue-driven milestone warrants and differing share prices for insiders to meet Nasdaq rules, is expected to strengthen liquidity as the company accelerates commercialization of RenovoCath, targets cash-flow breakeven, and funds full enrollment of its pivotal Phase III TIGeR-PaC trial in locally advanced pancreatic cancer by mid-2026, with trial results anticipated in 2027.

Investors are purchasing about 10.6 million shares (including pre-funded warrants) at $0.938 per share for institutions and a higher price for executives and directors, together with milestone warrants covering roughly half that amount, exercisable at a significant premium and expiring in 2029 or shortly after RenovoRx reports a qualifying revenue quarter. The structure of the high-premium, revenue-linked warrants and insider participation underscores investor confidence in RenovoRx’s commercial trajectory and oncology pipeline, while the company’s commitment to register resale of the new securities reflects efforts to provide liquidity to investors and support its positioning in the targeted oncology device and therapy market.

The most recent analyst rating on (RNXT) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

Spark’s Take on RNXT Stock

According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.

The score is held back primarily by weak financial performance—large operating losses and substantial cash burn despite improving revenue and a low-debt balance sheet. Technicals are comparatively supportive with the stock above major moving averages and positive MACD, while valuation is constrained by negative earnings. The latest earnings call was broadly positive on commercial expansion and trial progress, but this is partially offset by the Nasdaq bid-price compliance risk.

To see Spark’s full report on RNXT stock, click here.

More about RenovoRx

RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared, patented local drug-delivery device for use in the peripheral vascular system, including chemotherapeutic infusion. The company is also advancing its Trans-Arterial Micro-Perfusion (TAMP) therapy platform and an intra-arterial gemcitabine combination product (IAG) for locally advanced pancreatic cancer, supported by Orphan Drug Designations and an ongoing Phase III TIGeR-PaC trial.

Average Trading Volume: 298,249

Technical Sentiment Signal: Sell

Current Market Cap: $36.65M

For an in-depth examination of RNXT stock, go to TipRanks’ Overview page.